Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension

Journal of Hepatology

Volumn 65, Issue 4, 2016, Pages 692-699

  Mandorfer, Mattias ^a   Kozbial, Karin ^a   Schwabl, Philipp ^a   Freissmuth, Clarissa ^a   Schwarzer, Rémy ^a   Stern, Rafael ^a   Chromy, David ^a   Stättermayer, Albert Friedrich ^a   Reiberger, Thomas ^a   Beinhardt, Sandra ^a   Sieghart, Wolfgang ^a   Trauner, Michael ^a   Hofer, Harald ^a   Ferlitsch, Arnulf ^a   Ferenci, Peter ^a   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cirrhosis; Hepatitis C; Liver fibrosis; Portal hypertension; Viral hepatitis

Indexed keywords

DACLATASVIR; DASABUVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; INTERFERON;

ADULT; ARTICLE; CLINICAL EVALUATION; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PREDICTION; PRIORITY JOURNAL; TRANSIENT ELASTOGRAPHY; TREATMENT OUTCOME; TREATMENT PLANNING; ELASTOGRAPHY; LIVER CIRRHOSIS; SUSTAINED VIROLOGIC RESPONSE;

ELASTICITY IMAGING TECHNIQUES; HEPATITIS C; HUMANS; HYPERTENSION, PORTAL; INTERFERONS; LIVER CIRRHOSIS; SUSTAINED VIROLOGIC RESPONSE;

EID: 84991728705     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.05.027     Document Type: Article

References (35)

1. [1] Abraldes, J.G., Sarlieve, P., Tandon, P., Measurement of portal pressure. Clin Liver Dis 18 (2014), 779–792.
2. [2] La Mura, V., Nicolini, A., Tosetti, G., Primignani, M., Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement. World J Hepatol 7 (2015), 688–695.
3. [3] de Franchis, R., Baveno, V.I.F., Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 63 (2015), 743–752.
4. [4] Rincon, D., Ripoll, C., Lo Iacono, O., Salcedo, M., Catalina, M.V., Alvarez, E., et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 101 (2006), 2269–2274.
5. [5] Roberts, S., Gordon, A., McLean, C., Pedersen, J., Bowden, S., Thomson, K., et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol 5 (2007), 932–937.
6. [6] Reiberger, T., Payer, B.A., Ferlitsch, A., Sieghart, W., Breitenecker, F., Aichelburg, M.C., et al. A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin. Antivir Ther 17 (2012), 1327–1334.
7. [7] Reiberger, T., Rutter, K., Ferlitsch, A., Payer, B.A., Hofer, H., Beinhardt, S., et al. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 9 (2011), 602–608.
8. [8] C. Hezode H. Fontaine, Dorival, C., Zoulim, F., Larrey, D., Canva, V., et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 147 (2014), 132–142.
9. [9] Ferenci, P., Kozbial, K., Mandorfer, M., Hofer, H., HCV targeting of patients with cirrhosis. J Hepatol 63 (2015), 1015–1022.
10. [10] Charlton, M., Everson, G.T., Flamm, S.L., Kumar, P., Landis, C., Brown, R.S. Jr, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
11. [11] Mandorfer, M., Kozbial, K., Freissmuth, C., Schwabl, P., Stättermayer, A.F., Reiberger, T., et al. Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virologic responses. Aliment Pharmacol Ther 42 (2015), 707–718.
12. [12] Everson, G.T., Calleja, J.L., McCaughan, G., Bosch, J., Denning, J., Brainard, D.M., et al. LP13 Effect of long term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension. J Hepatol 62 (2015), S269–S270.
13. [13] Deterding, K., Honer Zu Siederdissen, C., Port, K., Solbach, P., Sollik, L., Kirschner, J., et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther 42 (2015), 889–901.
14. [14] Manns, M., Samuel, D., Gane, E.J., Mutimer, D., McCaughan, G., Buti, M., et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 16:6 (2016), 685–697.
15. [15] Afdhal, N., Everson, G.T., Calleja, J.L., McCaughan, G., Bosch, J., Denning, J., et al. LP13 Effect of long term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension. J Hepatol 62 (2015), S269–S270.
16. [16] Ferlitsch, A., Bota, S., Paternostro, R., Reiberger, T., Mandorfer, M., Heinisch, B., et al. Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient. Liver Int 35 (2015), 2115–2120.
17. [17] Reiberger, T., Ferlitsch, A., Payer, B.A., Pinter, M., Homoncik, M., Peck-Radosavljevic, M., et al. Non-selective beta-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. J Gastroenterol 47 (2011), 561–568.
18. [18] Schwabl, P., Bota, S., Salzl, P., Mandorfer, M., Payer, B.A., Ferlitsch, A., et al. New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. Liver Int 35 (2015), 381–390.
19. [19] Berzigotti, A., Rossi, V., Tiani, C., Pierpaoli, L., Zappoli, P., Riili, A., et al. Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension. J Gastroenterol 46 (2011), 687–695.
20. [20] Pinzani, M., Liver fibrosis in the Post-HCV Era. Semin Liver Dis 35 (2015), 157–165.
21. [21] Mandorfer, M., Schwabl, P., Steiner, S., Reiberger, T., Peck-Radosavljevic, M., Advances in the management of HIV/HCV coinfection. Hepatol Int 10 (2016), 424–435.
22. [22] Lens, S., Rincon, D., Garcia-Retortillo, M., Albillos, A., Calleja, J.L., Banares, R., et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin Gastroenterol Hepatol 13 (2015), 1846–1853.
23. [23] Sack, J., Garcia-Tsao, G., Variceal hemorrhage in a patient with HCV cirrhosis in whom liver synthetic function had normalized after viral elimination. Hepatology 63 (2016), 1733–1735.
24. [24] Villanueva, C., Albillos, A., Genesca, J., Abraldes, J.G., Calleja, J.L., Aracil, C., et al. Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension. Hepatology 63 (2016), 197–206.
25. [25] Ripoll, C., Groszmann, R.J., Garcia-Tsao, G., Bosch, J., Grace, N., Burroughs, A., et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 50 (2009), 923–928.
26. [26] Karlas, T., Benckert, J., Beer, S., Keim, V., Berg, T., Wiegand, J., Letter: can persisting liver stiffness indicate increased risk of HCC, after successful anti-HCV therapy?. Aliment Pharmacol Ther 43 (2016), 543–544.
27. [27] Mandorfer, M., Kozbial, K., Peck-Radosavljevic, M., Ferenci, P., Letter: can persisting liver stiffness indicate increased risk for HCC, after successful anti-HCV therapy? – Authors’ reply. Aliment Pharmacol Ther 43 (2016), 544–545.
28. [28] Afdhal, N., Asselah, T., Everson, G.T., Bosch, J., De-Oertel, S., Brainard, D.M., et al. LBP518 HCV eradication results in reduction of hepatic venous pressure gradient 48 weeks after end of treatment; final results of the study of sofosbuvir plus ribavirin in patients with cirrhosis and portal hypertension. J Hepatol 64 (2016), S221–S222.
29. [29] van der Meer, A.J., Maan, R., Veldt, B.J., Feld, J.J., Wedemeyer, H., Dufour, J.F., et al. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol 31:6 (2015), 1168–1176.
30. [30] Castera, L., Pinzani, M., Bosch, J., Non invasive evaluation of portal hypertension using transient elastography. J Hepatol 56 (2012), 696–703.
31. [31] Vizzutti, F., Arena, U., Romanelli, R.G., Rega, L., Foschi, M., Colagrande, S., et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 45 (2007), 1290–1297.
32. [32] Myers, R.P., Pomier-Layrargues, G., Kirsch, R., Pollett, A., Beaton, M., Levstik, M., et al. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J Hepatol 56 (2012), 564–570.
33. [33] de Ledinghen, V., Wong, V.W., Vergniol, J., Wong, G.L., Foucher, J., Chu, S.H., et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan(R). J Hepatol 56 (2012), 833–839.
34. [34] Cassinotto, C., Lapuyade, B., Ait-Ali, A., Vergniol, J., Gaye, D., Foucher, J., et al. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography–comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease. Radiology 269 (2013), 283–292.
35. [35] Sun, J., Xie, Q., Tan, D., Ning, Q., Niu, J., Bai, X., et al. GS02 Five-year on-treatment systematically monitoring of dynamic changes of liver stiffness measurement with transient elastography compared with paired liver biopsies in a randomized controlled trial in chronic hepatitis B patients. J Hepatol 64 (2016), S221–S222.